Investors should monitor Vera Therapeutics (VERA) ahead of its imminent FDA decision date, as positive clinical markers in kidney disease treatment could potentially double or triple the stock price. For high-risk speculative growth, Shaz (SHAZ) offers significant upside if it secures a contract with Anthropic, though it remains a "follow the smart money" play based on major insider ownership. In the software sector, HubSpot (HUBS) and Adobe (ADBE) are high-conviction picks viewed as resilient against the "SaaS apocalypse" due to their deep integration and essential tools for professional creators. While NVIDIA (NVDA) and Micron (MU) face short-term sentiment headwinds, Bloom Energy (BE) and Terawolf (WOLF) are actionable ways to play the critical energy infrastructure needs of AI data centers. Conversely, caution is advised for Capricor Therapeutics (CAPR) ahead of its July 29th FDA panel and Broadcom (AVGO), which the analyst is currently shorting due to perceived contract losses.

NVIDIA (NVDA)

• The speaker challenges the common perception of NVIDIA, asserting it is not just a hardware company, despite others in the discussion disagreeing. • Mention of rumors regarding delays for the Rubin architecture (reported by Semi Analysis). • Noted that NVIDIA has been a laggard recently compared to other semiconductor stocks like AMD.

Takeaways

• Sentiment: Neutral to Cautious. The speaker expressed uncertainty about the stock's immediate direction and noted it was "acting weak" despite a broader semiconductor rally. • Actionable Insight: Monitor the validity of the Rubin delay rumors, as the speaker suggests NVIDIA is a "master of catching up" even if initial reports of delays are true.

Micron Technology (MU)

• Identified as one of the most heavily traded stocks by value. • The speaker is currently Long but expressed frustration that the stock is "acting so weak" despite the AI thesis. • Discussion centered on whether the "AI bubble" is starting or ending, with a specific focus on memory supply and data center demand.

Takeaways

• Sentiment: Bullish but frustrated. • Actionable Insight: The speaker views memory as a non-monolith; investors should distinguish between different types of memory products rather than treating the sector as a single entity.

Vaxcyte (PCVX)

• A biotech company with an $8.3 billion market cap and $2.7 billion in cash. • Developing VAX-31, a pneumococcal vaccine intended to compete with Pfizer’s Prevnar. • The speaker analyzed the "Opus" clinical trials, noting that top-line results for Opus 1 are expected in Q4.

Takeaways

• Sentiment: Neutral/Skeptical. • Actionable Insight: The speaker believes the stock is already pricing in a 30% market share against giants like Pfizer and Merck, suggesting limited upside unless the data is "best-in-class." • Risk Factor: Vaccine commercialization requires ACIP recommendations, which can be a slow process.

Capricor Therapeutics (CAPR)

• A highly contentious mention; the speaker previously lost millions shorting this stock. • Discussion of a potential "inadvertent unblinding" of their clinical trial, which could compromise the data integrity. • The FDA is convening an expert panel (Advisory Committee/Adcom) on July 29th to review the drug.

Takeaways

• Sentiment: Bearish. • Risk Factor: The speaker suggests the company may have "fucked with the data" by changing the statistical plan from "relative change" to "mean change" after seeing preliminary results. • Actionable Insight: High-risk binary event approaching the July 29th Adcom.

Shaz (Ticker not explicitly provided, likely SHAZ)

• Described by the speaker as a "bizarre company" that "seems like a complete scam." • Despite the negative view of the management, the speaker is Long.

Takeaways

• Investment Thesis: The trade is based entirely on "Leopold" (a significant investor) owning 20% of the company. • Actionable Insight: If the company secures a contract with Anthropic, the speaker believes the stock could go up 5x to 10x. This is a high-risk "follow the smart money" play.

Vera Therapeutics (VERA)

• A biotech company focused on IgA nephropathy (a kidney disease). • The speaker performed a "scratch model" during the episode, noting a $3 billion market cap. • Mentioned a PDUFA (FDA decision date) is imminent.

Takeaways

• Sentiment: Bullish. • Actionable Insight: The speaker believes the stock could "double or triple" based on its ability to reduce proteinuria (protein in urine), which is a key clinical marker.

Investment Themes & Sectors

AI & Data Centers

• CoreWeave and Nebius: Mentioned in the context of Meta (META) potentially building its own cloud. The speaker debated if this is bearish for third-party providers or bullish for the overall sector demand. • Terawolf (WOLF): Rallied significantly (16%) on news of a 20-year lease agreement with Anthropic. • Bloom Energy (BE): Highlighted as a major player in solving the data center energy bottleneck.

Software as a Service (SaaS)

• HubSpot (HUBS): The speaker and guest discussed the "SaaS Apocalypse" and "Vibe Coding" (AI-generated code). They remain bullish on HubSpot due to its "easy button" appeal for SMBs and its deep API integration. • Adobe (ADBE): Viewed as "SaaS-proof" and "AI-proof" because professional creators require granular control that current AI cannot yet replicate perfectly.

Hedge Fund Strategies

• The speaker emphasizes that successful trading requires constant adaptation. He notes that "Value Investing" (in the traditional Ben Graham sense) is largely dead in the current market. • Actionable Insight: For uncorrelated alpha, investors must be nimble and willing to change strategies every few years, as "alpha" in a single strategy eventually disappears as others copy it.

Other Mentions

• Broadcom (AVGO): The speaker is Short, believing they are poorly positioned and losing TPU (Tensor Processing Unit) contracts. • PayPal (PYPL): Described as "really cheap" value play, but requires extreme patience. • Spruce Biosciences (SPRB): The speaker remains Long despite it being a "dogshit trade" thus far. • Krenetics (KHOT): Mentioned as a successful exit following an acquisition by Vertex.